Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.51 USD | +2.72% | +19.84% | -5.03% |
May. 01 | HC Wainwright Starts Cyclo Therapeutics With Buy Rating, $3 Price Target | MT |
Mar. 18 | Cyclo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Business Summary
Number of employees: 8
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Cyclodextrin-based Products
100.0
%
| 1 | 100.0 % | 1 | 100.0 % | -21.76% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 1 | 100.0 % | 1 | 100.0 % | -21.76% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Charles Strattan
FOU | Founder | 78 | 90-08-08 |
Scott Fine
CEO | Chief Executive Officer | 67 | 14-01-31 |
Joshua M. Fine
DFI | Director of Finance/CFO | 42 | 13-12-31 |
Jeffrey L. Tate
COO | Chief Operating Officer | 66 | 10-08-16 |
Michael Lisjak
LAW | General Counsel | 50 | 19-07-07 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Scott Fine
CEO | Chief Executive Officer | 67 | 14-01-31 |
Charles Strattan
FOU | Founder | 78 | 90-08-08 |
William Shanahan
BRD | Director/Board Member | 84 | 16-06-06 |
Chairman | 58 | 14-01-31 | |
Vivien Wong
BRD | Director/Board Member | 67 | 23-08-16 |
Shawn Cross
BRD | Director/Board Member | 56 | Dec. 26 |
Jeffrey L. Tate
COO | Chief Operating Officer | 66 | 10-08-16 |
F. Ostronic
BRD | Director/Board Member | 68 | 14-04-08 |
Randall Toig
BRD | Director/Board Member | 73 | 18-03-19 |
William Conkling
BRD | Director/Board Member | 53 | 23-05-01 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 28,715,740 | 17,378,910 ( 60.52 %) | 0 | 60.52 % |
Company contact information
Cyclo Therapeutics, Inc.
6714 NW 16th Street Suite B
32653, Gainesville
+
http://www.cyclotherapeutics.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.03% | 43.36M | |
+26.08% | 662B | |
+21.85% | 546B | |
-4.77% | 359B | |
+16.97% | 323B | |
+5.69% | 290B | |
+13.68% | 234B | |
+3.65% | 198B | |
-11.12% | 194B | |
-3.40% | 157B |
- Stock Market
- Equities
- CYTH Stock
- Company Cyclo Therapeutics, Inc.